All In Biotech

Drug Trial Radar · NCT07821944

A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate in Adults With Hyperlipidemia in India

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Nov 26, 2027

Study completion Nov 26, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.

Conditions

  • Hyperlipidemia
  • Hypercholesterolemia

Interventions

  • Enlicitide DecanoateDrug

    Oral administration

  • PlaceboOther

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 32 Weeks
  3. Number of Participants who Discontinue Study Drug Due to One or More AEsTime frame: Up to approximately 24 Weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • KLES Prabhakar Kore Hospital & Medical Research Centre [M] ( Site 1004)

    Belagavi, Karnataka, India · Recruiting

  • Sir Ganga Ram Hospital ( Site 1001)

    New Delhi, National Capital Territory of Delhi, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.